Cytomegalovirus-RNA Accurately Identifies Clinically Significant Infection Needing Preemptive Therapy in Liver...

Area of Science:

• Virology
• Pediatric Transplantation
• Immunology

Background:

• Preemptive therapy (PET) manages Cytomegalovirus (CMV) infection post-pediatric liver transplant (LT).
• Current monitoring relies on CMV-DNA, but early low levels may not indicate active replication, risking viremic breakthroughs.
• Identifying active viral replication is crucial for timely intervention.

Purpose of the Study:

• To assess quantitative CMV-RNA (UL21.5 mRNA) for detecting active CMV replication.
• To evaluate CMV-RNA's accuracy in identifying clinically significant CMV infection (csCMVi) requiring PET in pediatric LT recipients.

Main Methods:

• Prospective study of 12 children following LT over 6 months.
• Collected 144 paired quantitative CMV-RNA and CMV-DNA samples.
• Compared CMV-RNA and CMV-DNA levels to identify active replication and csCMVi.

Main Results:

• CMV-RNA was positive in 17/52 (32%) CMV-DNA positive specimens; undetectable in all CMV-DNA negative specimens.
• All children with csCMVi showed early detectable CMV-RNA, peaking with CMV-DNA.
• Children with persistently low CMV-DNAemia did not have detectable CMV-RNA.

Conclusions:

• Quantitative CMV-RNA demonstrated 100% sensitivity and specificity in identifying pediatric LT patients needing PET.
• Early CMV-RNA detection signifies significant CMV infection/reactivation.
• CMV-RNA can help avoid unnecessary antiviral treatment by enabling precise intervention timing.